Clinical Trials Logo

Clinical Trial Summary

The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Eligible participants receive cultured thymus tissue for implantation and may undergo biopsy. Immune suppression may be given depending on the immune status and clinical condition of the participant. Immune function testing is continued for one year post-implantation.


Clinical Trial Description

The patients enrolled have a high likelihood of death if they do not receive culture thymus tissue because of lack of thymus function. As there are many types of patients who may be enrolled, study results will not have statistical significance. The study objective is to make cultured thymus tissue available for implantation on an expanded access basis. Data will be collected on survival, naïve T cell development, T cell chimerism, and implant related toxicities, as well as any unexpected study-related serious adverse events. Eligible subjects receive cultured thymus tissue and may undergo allograft biopsy. Immune suppression may be given depending on the subject's immune status and clinical condition. Protocol specified studies continue until approximately one year post-implantation. Study participation lasts approximately two years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02274662
Study type Expanded Access
Source Enzyvant Therapeutics GmBH
Contact
Status Approved for marketing
Phase

See also
  Status Clinical Trial Phase
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Completed NCT04553705 - Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19) Phase 2/Phase 3
Completed NCT00758992 - Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages N/A
Recruiting NCT05907746 - Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency Phase 2
Active, not recruiting NCT02291965 - Blood Samples to Identify Biomarkers of Busulfan
Recruiting NCT04408950 - Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
Completed NCT00923364 - Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC Phase 2
Withdrawn NCT05672654 - Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients N/A
Recruiting NCT05405491 - Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation N/A
Recruiting NCT01800643 - Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Phase 2/Phase 3
Recruiting NCT00001467 - Genetic Analysis of Immune Disorders
Not yet recruiting NCT04447937 - Immunodeficiency in MS
Completed NCT00925925 - Epigenetic Markers of B-Cell Function in Low Birth Weight Infants N/A
Recruiting NCT01861106 - Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations Phase 2
Recruiting NCT06248957 - SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
Suspended NCT05027945 - A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Phase 2
Active, not recruiting NCT05655546 - ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals N/A
Completed NCT03374566 - Immunodeficiency for Severe Epstein-Barr Virus Infection
Terminated NCT01027702 - Donor Lymphocyte Infusion After Alternative Donor Transplantation Phase 1/Phase 2